{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:04:46Z","timestamp":1791288286987,"version":"4.3.0"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,27]],"date-time":"2012-02-27T00:00:00Z","timestamp":1330300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031046","type":"journal-article","created":{"date-parts":[[2012,2,27]],"date-time":"2012-02-27T22:10:31Z","timestamp":1330380631000},"page":"e31046","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":92,"title":["A Pilot Study of IL-2R\u03b1 Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00626015","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John H.","family":"Sampson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schmittling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Congdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita K.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Reap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Coan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Vredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy.","volume":"6","author":"W Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.","volume":"188","author":"AM Thornton","year":"1998","journal-title":"J Exp Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.193.11.1285","article-title":"Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.","volume":"193","author":"H Jonuleit","year":"2001","journal-title":"J Exp Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.193.11.1303","article-title":"Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.","volume":"193","author":"D Dieckmann","year":"2001","journal-title":"J Exp Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.","volume":"4","author":"JD Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","article-title":"An essential role for Scurfin in CD4+CD25+ T regulatory cells.","volume":"4","author":"R Khattri","year":"2003","journal-title":"Nat Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0167-5699(93)90180-S","article-title":"Saying the \u2018S\u2019 word in public.","volume":"14","author":"DR Green","year":"1993","journal-title":"Immunol Today"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.","volume":"155","author":"S Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.184.2.387","article-title":"Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.","volume":"184","author":"M Asano","year":"1996","journal-title":"J Exp Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","article-title":"B7\/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.","volume":"12","author":"B Salomon","year":"2000","journal-title":"Immunity"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.4049\/jimmunol.165.6.3105","article-title":"CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25\u2212 subpopulations.","volume":"165","author":"LA Stephens","year":"2000","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1084\/jem.165.1.146","article-title":"Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance.","volume":"165","author":"O Taguchi","year":"1987","journal-title":"J Exp Med"},{"key":"ref13","first-page":"365","article-title":"Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens.","volume":"82","author":"O Taguchi","year":"1994","journal-title":"Immunology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1084\/jem.189.2.279","article-title":"Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(\u2212) thymocytes.","volume":"189","author":"B Seddon","year":"1999","journal-title":"J Exp Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1084\/jem.189.5.877","article-title":"Peripheral autoantigen induces regulatory T cells that prevent autoimmunity.","volume":"189","author":"B Seddon","year":"1999","journal-title":"J Exp Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/intimm\/dxf105","article-title":"Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease.","volume":"14","author":"H Bagavant","year":"2002","journal-title":"Int Immunol"},{"key":"ref17","first-page":"5267","article-title":"Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+\/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.","volume":"62","author":"R Somasundaram","year":"2002","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.","volume":"10","author":"TJ Curiel","year":"2004","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.","volume":"169","author":"UK Liyanage","year":"2002","journal-title":"J Immunol"},{"key":"ref20","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients.","volume":"9","author":"AM Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref21","first-page":"4404","article-title":"Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.","volume":"9","author":"F Ichihara","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref22","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.","volume":"61","author":"EY Woo","year":"2001","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.","volume":"66","author":"PE Fecci","year":"2006","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.","volume":"112","author":"MA Morse","year":"2008","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.","volume":"115","author":"J Dannull","year":"2005","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.cji.0000175468.19742.10","article-title":"Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.","volume":"28","author":"P Attia","year":"2005","journal-title":"J Immunother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.4049\/jimmunol.179.7.4919","article-title":"Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.","volume":"179","author":"DJ Powell Jr","year":"2007","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1983","DOI":"10.1371\/journal.pone.0001983","article-title":"Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.","volume":"3","author":"JF Curtin","year":"2008","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0966-3274(00)00021-6","article-title":"Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.","volume":"8","author":"J Goebel","year":"2000","journal-title":"Transpl Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-06-0053","article-title":"Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.","volume":"12","author":"PE Fecci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.4049\/jimmunol.176.6.3301","article-title":"Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.","volume":"176","author":"AP Kohm","year":"2006","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/1078-0432.CCR-10-1757","article-title":"Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I\/II Study in Metastatic Melanoma Patients.","volume":"16","author":"JF Jacobs","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref33","article-title":"Monoclonal antibody blockade of IL-2R{alpha} during lymphopenia selectively depletes regulatory T cells in mice and humans.","author":"DA Mitchell","year":"2011","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1073\/pnas.87.11.4207","article-title":"Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.","volume":"87","author":"PA Humphrey","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","first-page":"3140","article-title":"Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.","volume":"55","author":"CJ Wikstrand","year":"1995","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.4049\/jimmunol.173.10.6472","article-title":"Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).","volume":"173","author":"E Purev","year":"2004","journal-title":"J Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-06-0913","article-title":"Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.","volume":"12","author":"JC Sok","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.","volume":"13","author":"JH Sampson","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.","volume":"28","author":"JH Sampson","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-09-0124","article-title":"An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.","volume":"8","author":"JH Sampson","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-06-3919","article-title":"Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.","volume":"67","author":"M Binder","year":"2007","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.","volume":"103","author":"B Bielekova","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.","volume":"202","author":"L Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.","volume":"100","author":"GQ Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.","volume":"23","author":"P Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.","volume":"142","author":"SH Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.","volume":"28","author":"JA Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.","volume":"201","author":"R Setoguchi","year":"2005","journal-title":"J Exp Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.4049\/jimmunol.176.8.4632","article-title":"Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it.","volume":"176","author":"DC Neujahr","year":"2006","journal-title":"J Immunol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1084\/jem.20080099","article-title":"Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.","volume":"205","author":"SA Quezada","year":"2008","journal-title":"J Exp Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.","volume":"117","author":"C Wrzesinski","year":"2007","journal-title":"J Clin Invest"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.","volume":"102","author":"E Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/0008-5472.CAN-06-2903","article-title":"Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.","volume":"67","author":"S Nair","year":"2007","journal-title":"Cancer Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1158\/1078-0432.CCR-08-1156","article-title":"Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.","volume":"14","author":"K Koyama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.4049\/jimmunol.0902238","article-title":"An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.","volume":"185","author":"JF Martin","journal-title":"J Immunol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0041-1345(98)00571-5","article-title":"Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.","volume":"30","author":"F Vincenti","year":"1998","journal-title":"Transplant Proc"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gut.2005.089854","article-title":"Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.","volume":"55","author":"G Van Assche","year":"2006","journal-title":"Gut"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.immuni.2009.11.015","article-title":"Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes.","volume":"32","author":"A Boissonnas","year":"2010","journal-title":"Immunity"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CJI.0b013e31815dc0e8","article-title":"Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.","volume":"31","author":"DJ Powell Jr","year":"2008","journal-title":"J Immunother"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.cji.0000187959.45803.0c","article-title":"Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.","volume":"29","author":"P Attia","year":"2006","journal-title":"J Immunother"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ni1105-1071","article-title":"Fueling regulation: IL-2 keeps CD4+ Treg cells fit.[comment].","volume":"6","author":"KJ Maloy","year":"2005","journal-title":"Nat Immunol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/ni1264","article-title":"Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling.","volume":"6","author":"LM D'Cruz","year":"2005","journal-title":"Nat Immunol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells.","volume":"6","author":"JD Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2.","volume":"4","author":"TR Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"ref65","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.","volume":"59","author":"S Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.","volume":"174","author":"PA Antony","year":"2005","journal-title":"J Immunol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.20041130","article-title":"Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.","volume":"200","author":"MJ Turk","year":"2004","journal-title":"J Exp Med"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","article-title":"Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.","volume":"441","author":"MA Williams","year":"2006","journal-title":"Nature"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/neuonc\/nor134","article-title":"Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.","volume":"13","author":"DA Wainwright","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1215\/15228517-2007-035","article-title":"Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.","volume":"10","author":"DA Mitchell","year":"2008","journal-title":"Neuro Oncol"},{"key":"ref71","first-page":"3347","article-title":"Human cytomegalovirus infection and expression in human malignant glioma.","volume":"62","author":"CS Cobbs","year":"2002","journal-title":"Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMc0804818","article-title":"Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.","volume":"359","author":"RM Prins","year":"2008","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00401-008-0359-1","article-title":"Detection of human cytomegalovirus in different histological types of gliomas.","volume":"116","author":"ME Scheurer","year":"2008","journal-title":"Acta Neuropathol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"R Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-05-0464","article-title":"Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.","volume":"11","author":"LM Liau","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jim.2008.08.004","article-title":"Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.","volume":"339","author":"RJ Schmittling","year":"2008","journal-title":"J Immunol Methods"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T20:28:04Z","timestamp":1687292884000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031046"}},"subtitle":[],"editor":[{"given":"Maciej S.","family":"Lesniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,27]]},"references-count":76,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031046","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,27]]}}}